Literature DB >> 8166523

Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas.

L A Robinson1, A L Moulton, W H Fleming, A Alonso, T A Galbraith.   

Abstract

Acute multiloculated thoracic empyemas incompletely drained by tube thoracostomy alone usually require operation. To avoid a thoracotomy yet treat this difficult problem, intrapleural fibrinolytic agents were employed. Between April 1, 1990, and April 1, 1993, 13 consecutive patients presenting with a fibrinopurulent empyema were demonstrated to have incomplete drainage. To facilitate drainage, streptokinase, 250,000 units in 100 mL 0.9% saline solution (3 patients), or urokinase, 100,000 units in 100 mL 0.9% saline solution (10 patients), was instilled daily into the chest tube, and the tube was clamped for 6 to 12 hours followed by suction. This routine was continued daily for a mean of 6.8 +/- 3.7 days (range, 1 to 14 days) until resolution of the pleural fluid collection was demonstrated by computed chest tomography and clinical indications. This regimen was completely successful in 10 of 13 patients (77%), who had resolution of the empyema, eventual withdrawal of chest tubes, and no recurrence. Two patients, both pediatric liver transplant patients, had an initial good response but eventually required decortication. One patient with a good radiographic response became increasingly febrile during streptokinase therapy and underwent a thoracotomy, but no significant undrained fluid was found. This patient's continued fever was believed to be a streptokinase reaction. Urokinase was used subsequently. No treatment-related mortalities or complications occurred. Intrapleural fibrinolytic agents, especially urokinase, are safe, cost-effective means of facilitating complete chest tube drainage, thereby avoiding the morbidity of a major thoracotomy for 77% of a group of multiloculated empyema patients who traditionally would have required open surgical therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166523     DOI: 10.1016/0003-4975(94)90180-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Less is best? The impact of urokinase as the first line management of empyema thoracis.

Authors:  B A Khalil; P A Corbett; M O Jones; C T Baillie; Kevin Southern; P D Losty; S E Kenny
Journal:  Pediatr Surg Int       Date:  2006-09-30       Impact factor: 1.827

3.  Intrapleural administration of streptokinase in complicated purulent pleural effusion: a CT-guided strategy.

Authors:  E Roupie; K Bouabdallah; C Delclaux; C Brun-Buisson; F Lemaire; N Vasile; L Brochard
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

4.  Intrapleural fibrinolytic treatment of multiloculated pediatric empyemas.

Authors:  Refik Ulkü; Abdurrahman Onen; Serdar Onat; Nihal Kilinç; Cemal Ozçelik
Journal:  Pediatr Surg Int       Date:  2004-06-08       Impact factor: 1.827

5.  Complicated parapneumonic effusion and empyema: pleural decortication and video-assisted thoracic surgery.

Authors:  Shi-Ping Luh; Gwo-Jong Hsu; Chen Cheng-Ren
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

6.  Intrapleural therapy in management of complicated parapneumonic effusions and empyema.

Authors:  Alaeldin H Ahmed; Tariq E Yacoub
Journal:  Clin Pharmacol       Date:  2010-11-22

7.  Review of video-assisted thoracoscopy in children.

Authors:  S N Oak; S V Parelkar; K V Satishkumar; R Pathak; B H Ramesh; S Sudhir; M Keshav
Journal:  J Minim Access Surg       Date:  2009 Jul-Sep       Impact factor: 1.407

Review 8.  Minimally invasive thoracic surgery in pediatric patients: the Taiwan experience.

Authors:  Yu-Kai Huang; Chieh Chou; Chung-Liang Li; Hui-Gin Chiu; Yu-Tang Chang
Journal:  Biomed Res Int       Date:  2013-05-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.